Latest Updates in PCOD/PCOS (2025-2026)

1. LANDMARK: PCOS Has Been Renamed PMOS

• The term "polycystic ovary syndrome" was recognized as clinically inaccurate - a substantial proportion of diagnosed patients do not have ovarian cysts at all
• "Polycystic" misdirected clinical attention toward the ovaries, obscuring the condition's core polyendocrine and metabolic nature
• The old name contributed to delayed diagnosis, fragmented care, and patient stigma
• It curtailed broader research and policy framing

• 56 leading academic, clinical, and patient organizations worldwide
• Surveys from over 14,300 patients and multidisciplinary health professionals from all world regions (surveys in 2017, 2023, April 2025, and January 2026)
• Serial nominal group workshops in November 2025 and February 2026
• Agreement on the new name in February 2026

• Poly-endocrine - reflects multiple hormonal disruptions (androgens, insulin, AMH, LH/FSH)
• Metabolic - highlights insulin resistance, dyslipidemia, and cardiometabolic risk
• Ovarian - retains the reproductive/ovarian dimension
• Syndrome - acknowledges the multisystem, heterogeneous nature

2. GLP-1 Receptor Agonists: Emerging as a Key Treatment

• 176 participants from 4 RCTs
• GLP-1 RAs significantly reduced:
  • Waist circumference (mean -5.16 cm)
  • BMI (mean -2.42)
  • Serum triglycerides
  • Total testosterone (mean -1.33 nmol/L)
• Main side effects: nausea and abdominal pain (mild)

• GLP-1 RAs outperformed both placebo and metformin in reducing BMI, body weight, waist circumference, waist-to-hip ratio, fasting insulin, 2-hour OGTT glucose, and HOMA-IR
• Significant increases in nausea, vomiting, and dizziness noted
• Long-term effects on lipid profiles still need further study

3. N-Acetylcysteine (NAC): Renewed Evidence

• NAC significantly increased progesterone and endometrial thickness vs. placebo and other drugs
• Raised LH levels compared to metformin
• Being explored as an adjunct or alternative to metformin, with better tolerability

4. Probiotics/Synbiotics: Emerging Adjunct Role

• Showed promising results for improving insulin resistance and hormonal imbalance
• Gut microbiome modulation is becoming an active research area in PCOS

5. Genetics: Major GWAS Findings (2025)

• 12,419 Chinese + 13,773 European PCOS cases analyzed
• Identified 94 independent genetic loci, 73 previously unreported
• Highlighted Anti-Mullerian Hormone (AMH) as a disease-causing gene
• Identified granulosa cells as central to PCOS development
• Revealed PPARG signaling pathway involvement - opens door to precision/targeted therapy
• Substantial genetic overlap between Chinese and European ancestries confirmed

6. Cardiovascular Risk: Elevated Concern

• Non-obese young women with PCOS are at high long-term cardiovascular risk
• Cardiovascular risk factor assessment in PCOS/PMOS is now emphasized more strongly in clinical practice

7. Adolescent PCOS: Increased Focus

• An estimated 70% of PCOS cases remain undiagnosed
• Adolescents are especially under-diagnosed
• Untreated adolescent PCOS carries risk of developing type 2 diabetes, cardiovascular disease, NAFLD, and endometrial cancer in early adulthood

8. Lifestyle Interventions: Still First-Line

Summary Table